Australia - engleză - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - gentamicin sulfate, quantity: 4.17 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; disodium edetate - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - gentamicin sulfate, quantity: 4.17 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; disodium edetate - for the treatment of infections due to one or more susceptible strains of bacteria, including pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella, enterobacter and serratia species and staphylococcus (including strains resistant to other antibiotics). gentamicin may also be used for the treatment of the following conditions when caused by susceptible organisms: bacteraemia, respiratory tract infections, urinary tract infections, skin and skin structure infections, bone infections, peritonitis, septic abortion and burns complicated by sepsis. aminoglycosides, including gentamicin are generally not indicated in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to less toxic antibiotics. in suspected or documented gram-negative sepsis, gentamicin should be considered for initial antimicrobial therapy. therapy may be instituted before obtaining results of susceptibility tests. the decision to continue therapy is based on results of the susceptibility tests, the severity of the infection and risk toxicity. if anaerobic organisms are suspected, antimicrobial therapy in addition to the gentamicin regimen should be considered.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

agri laboratories, ltd. - urea (unii: 8w8t17847w) (urea - unii:8w8t17847w) - for use as an antiseptic and proteolytic aid in beef and dairy cattle and sheep.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - human immunoglobulin g (unii: 66y330cjhs) (human immunoglobulin g - unii:66y330cjhs) - panzyga is indicated for treatment of primary humoral immunodeficiency (pi) in patients 2 years of age and older. this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, x-linked agammaglobulinemia, wiskott-aldrich syndrome, and severe combined immunodeficiencies. panzyga is indicated for the treatment of adult patients with itp to raise platelet counts to control or prevent bleeding. panzyga is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (cidp) to improve neuromuscular disability and impairment. - panzyga is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin. - panzyga is contraindicated in iga-deficient patients with antibodies against iga and history of hypersensitivity . risk summary no human data are available to indicate the presence or absence of drug-associated risk. animal reproduction studies have not been conducted

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

maia pharmaceuticals, inc. - baclofen (unii: h789n3fke8) (baclofen - unii:h789n3fke8) - baclofen injection (intrathecal) is indicated for use in the management of severe spasticity. patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. for spasticity of spinal cord origin, chronic infusion of baclofen injection (intrathecal) via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable cns side effects at effective doses. patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. baclofen injection (intrathecal) is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only in implantable pumps approved by the fda specifically for the administration of baclofen injection (intrathecal) into the intrathecal space. spasticity of spinal cord origin: evidence su

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

piramal critical care inc - oxacillin sodium (unii: g0v6c994q5) (oxacillin - unii:uh95vd7v76) - oxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see clinical pharmacology: susceptibility testing ). oxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. oxacillin should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with oxacillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of oxacillin for injection, usp and other antibacterial drugs, oxacillin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspecte

Australia - engleză - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - noradrenaline (norepinephrine) acid tartrate monohydrate, quantity: 20 mg (equivalent: noradrenaline (norepinephrine), qty 10 mg) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sumpathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion and drug reactions).,as an adjunct in the treatment of cardiac arrest. to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - noradrenaline (norepinephrine) acid tartrate monohydrate, quantity: 12 mg (equivalent: noradrenaline (norepinephrine), qty 6 mg) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sumpathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion and drug reactions).,as an adjunct in the treatment of cardiac arrest. to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - noradrenaline (norepinephrine) acid tartrate monohydrate, quantity: 10 mg (equivalent: noradrenaline (norepinephrine), qty 5 mg) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sumpathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion and drug reactions).,as an adjunct in the treatment of cardiac arrest. to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - noradrenaline (norepinephrine) acid tartrate monohydrate, quantity: 6 mg (equivalent: noradrenaline (norepinephrine), qty 3 mg) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion and drug reactions).,as an adjunct in the treatment of cardiac arrest. to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.